These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 21733929

  • 1. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
    Marin L, Koivula MK, Jukkola-Vuorinen A, Leino A, Risteli J.
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
    [Abstract] [Full Text] [Related]

  • 2. Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide.
    Koivula MK, Ruotsalainen V, Björkman M, Nurmenniemi S, Ikäheimo R, Savolainen K, Sorva A, Risteli J.
    Ann Clin Biochem; 2010 Jan; 47(Pt 1):67-71. PubMed ID: 19940208
    [Abstract] [Full Text] [Related]

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Jan; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 4. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R, Thölix E.
    Anticancer Res; 1996 Jan; 16(4B):2289-93. PubMed ID: 8694558
    [Abstract] [Full Text] [Related]

  • 5. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 6. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, Yasui H, Yuda H, Sakai T, Kaneda M, Adachi Y.
    Cancer; 1999 May 01; 85(9):1951-7. PubMed ID: 10223235
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
    Lüftner D, Jozereau D, Schildhauer S, Geppert R, Müller C, Fiolka G, Wernecke KD, Possinger K.
    Anticancer Res; 2005 May 01; 25(3A):1491-9. PubMed ID: 16033050
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.
    Chrapko BE, Nocuń A, Gołebiewska R, Jankowska H, Zaorska-Rajca J.
    Nucl Med Rev Cent East Eur; 2005 May 01; 8(2):100-4. PubMed ID: 16437394
    [Abstract] [Full Text] [Related]

  • 14. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W, Muley T, Herb KP, Schmidt-Gayk H.
    Anticancer Res; 2004 May 01; 24(5B):3193-201. PubMed ID: 15510610
    [Abstract] [Full Text] [Related]

  • 15. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y, Tokue A.
    Nihon Rinsho; 1998 Aug 01; 56(8):2072-6. PubMed ID: 9750510
    [Abstract] [Full Text] [Related]

  • 16. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity.
    Han B, Copeland M, Geiser AG, Hale LV, Harvey A, Ma YL, Powers CS, Sato M, You J, Hale JE.
    J Proteome Res; 2007 Nov 01; 6(11):4218-29. PubMed ID: 17924680
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
    Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E.
    J Urol; 2007 Sep 01; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
    [Abstract] [Full Text] [Related]

  • 19. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M, Yonese J, Fukui I, Ogata E.
    J Urol; 2002 Apr 01; 167(4):1863-6. PubMed ID: 11912449
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.